Please assess the completion status of the following clinical trial:

Trial Title: Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Patients Infected With Burkholderia Cepacia Complex

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 6 years or older~* Diagnosis of CF based on the following: sweat chloride\>60 mEq/L or genotype with 2 identifiable mutations consistent with CF; and one or more clinical features consistent with CF.~* Chronically infected with a Burkholderia cepacia complex species (\>50% of respiratory specimens positive in the 24 months prior to screening).~* Able to produce sputum (expectorated or induced).~* Able to reproducibly perform pulmonary function testing.~* Written informed consent provided.~Exclusion Criteria:~* Post lung transplantation.~* Pregnancy.~* Acute exacerbation requiring IV or oral antibiotics within 14 days~* Patients currently receiving inhaled tobramycin/TOBI~* A septic or clinically unstable patient, as determined by the investigator.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TOBI Podhaler (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).